United Therapeutics Corporation announced its financial results for the third quarter ended September 30, 2024, reporting a 23% year-over-year increase in total revenues to $748.9 million. Net income for the quarter grew 16% to $309.1 million, with diluted earnings per share reaching $6.39, up 19% from the prior year.
The company's treprostinil franchise continued to drive growth, with total Tyvaso revenues increasing 33% to $433.8 million. Orenitram and Unituxin also contributed positively, with revenues growing 23% to $113.2 million and 19% to $61.1 million, respectively, while Remodulin revenues saw a slight decrease of 2% to $128.3 million.
United Therapeutics also confirmed the completion of its $1.0 billion accelerated share repurchase program in September 2024, which resulted in the repurchase of 3,547,374 shares of common stock. The company accrued a liability of $65.1 million related to ongoing litigation with Sandoz Inc. during the quarter.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.